Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Claudio Conrad"'
Autor:
Danielle M.M. Harris, Silke Szymczak, Sven Schuchardt, Johannes Labrenz, Florian Tran, Lina Welz, Hanna Graßhoff, Henner Zirpel, Melike Sümbül, Mhmd Oumari, Nils Engelbogen, Ralf Junker, Claudio Conrad, Diamant Thaçi, Norbert Frey, Andre Franke, Stephan Weidinger, Bimba Hoyer, Philip Rosenstiel, Silvio Waschina, Stefan Schreiber, Konrad Aden
Publikováno v:
EBioMedicine, Vol 102, Iss , Pp 105056- (2024)
Summary: Background: Chronic inflammatory diseases (CIDs) are systems disorders that affect diverse organs including the intestine, joints and skin. The essential amino acid tryptophan (Trp) can be broken down to various bioactive derivatives importa
Externí odkaz:
https://doaj.org/article/dec1a5c50cfb47d881f49ff39ebb0105
Autor:
Florian Richter, Claudio Conrad, Julia Hoffmann, Benedikt Reichert, Witigo von Schoenfels, Clemens Schafmayer, Jan-Hendrik Egberts, Thomas Becker, Mark Ellrichmann
Publikováno v:
Medicina, Vol 60, Iss 7, p 1105 (2024)
Background and Objectives: Anastomotic insufficiencies (AI) and perforations of the upper gastrointestinal tract (uGIT) result in high morbidity and mortality. Endoscopic stent placement and endoluminal vacuum therapy (EVT) have been established as s
Externí odkaz:
https://doaj.org/article/97f3a87ced904e609607cbd8d9739fad
Autor:
Neha Mishra, Konrad Aden, Johanna I. Blase, Nathan Baran, Dora Bordoni, Florian Tran, Claudio Conrad, Diana Avalos, Charlot Jaeckel, Michael Scherer, Signe B. Sørensen, Silja H. Overgaard, Berenice Schulte, Susanna Nikolaus, Guillaume Rey, Gilles Gasparoni, Paul A. Lyons, Joachim L. Schultze, Jörn Walter, Vibeke Andersen, SYSCID Consortium, Emmanouil T. Dermitzakis, Stefan Schreiber, Philip Rosenstiel
Publikováno v:
Genome Medicine, Vol 14, Iss 1, Pp 1-20 (2022)
Abstract Background and aims Treatment with tumor necrosis factor α (TNFα) antagonists in IBD patients suffers from primary non-response rates of up to 40%. Biomarkers for early prediction of therapy success are missing. We investigated the dynamic
Externí odkaz:
https://doaj.org/article/533221e6756c4c1d84dece9aba5649b6
Autor:
Carina Saggau, Frank Leypoldt, Claudio Conrad, Ina Schröder, Yascha Khodamoradi, Justina Dargvainiene, Oliver A. Cornely, Petra Bacher, Robert Markewitz, Elisa Rosati, Alexander Scheffold, Daniela Esser, Philip Rosenstiel, Esther Schiminsky, Maria J G T Vehreschild, Klaus Peter Wandinger, Matthias Kochanek, Fabian J. Eberhardt, Holger Neb, Andre Franke, Jan Rybniker, Michael Sonntagbauer, Imke Wieters, Gabriela Rios Martini, Florian Tran, Max Augustin, Philipp Koehler
Publikováno v:
Immunity
CD4+ T cells reactive against SARS-CoV-2 can be found in unexposed individuals and these are suggested to arise in response to common cold corona viruses (CCCoVs) infection. Here, we utilized SARS-CoV-2-reactive CD4+ T cell enrichment to examine the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2191aa3b2bed7e552c03ac06a24c9213
https://pubmed.ncbi.nlm.nih.gov/33296686
https://pubmed.ncbi.nlm.nih.gov/33296686
Autor:
Jan Rybniker, Philipp Koehler, Carina Saggau, Esther Schiminsky, Andre Franke, Gabriela Rios Martini, Imke Wieters, Michael Sonntagbauer, Justina Dargvainiene, Holger Neb, Klaus-Peter Wandinger, Maria J G T Vehreschild, Claudio Conrad, Yascha Khodamoradi, Petra Bacher, Frank Leypoldt, Daniela Esser, Alexander Scheffold, Fabian J. Eberhardt, Elisa Rosati, Oliver A. Cornely, Robert Markewitz, Ina Schr oumlder, Florian Tran, Philip Rosenstiel, Matthias Kochanek
SummaryCoronavirus disease 2019 (COVID-19) displays high clinical variability but the parameters that determine disease severity are still unclear. Pre-existing T cell memory has been hypothesized as a protective mechanism but conclusive evidence is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2525adf582b3bddbba6b78834cb49f03
https://doi.org/10.1101/2020.09.15.20188896
https://doi.org/10.1101/2020.09.15.20188896
Autor:
Susanna Nikolaus, Minhu Chen, Birgitte Buur Rasmussen, Claudio Conrad, Friedrich Feuerhake, Valery Volk, Florian Tran, Lennart Lenk, Ian Cottingham, Johannes Bethge, Georg H. Waetzig, Stefan Schreiber, Neha Mishra, Konrad Aden, Stefan Rose-John, Hanna Höper, Christoph Röcken, Joana P. Bernardes, Philip Rosenstiel, Christoph Garbers, Juliane Lokau, T Kühbacher, Johanna I. Blase, Niclas Petri
Publikováno v:
Gastroenterology
Background & Aims A large unmet therapeutic need exists in inflammatory bowel disease (IBD). Inhibition of interleukin (IL)-6 appears to be effective, but the therapeutic benefit of a complete IL6/IL6 receptor (IL6R) blockade is limited by profound i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09f5566b3ffead2e3aa4f94e29b015b1
https://doi.org/10.1053/j.gastro.2021.02.062
https://doi.org/10.1053/j.gastro.2021.02.062
Autor:
Berenice Schulte, Johannes Bethge, Anne Strigli, Dieter Kabelitz, Henriette Ebsen, Elisa Rosati, Dörthe Schuldt, Sebastian Zeissig, Claudio Conrad, Susanna Nikolaus, Konrad Aden, Maren Paulsen, Anupam Sinha, Andre Franke, C. Marie Dowds, Stefan Schreiber, Wei Hung Pan, Marlies Marx, Sabin-Christin Kornell, Alexander Arlt, Neha Mishra, Ulf Lützen, Philip Rosenstiel, Maaz Zuhayra, Mark Ellrichmann
Publikováno v:
Gut
ObjectiveVedolizumab, a monoclonal antibody directed against the integrin heterodimer α4β7, is approved for the treatment of Crohn’s disease and ulcerative colitis. The efficacy of vedolizumab has been suggested to result from inhibition of intes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::226faf18785dffdb2de2353f823e11a8
Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis
Autor:
Claudio Conrad, Stefan Schreiber, Silvia Meffert, Susanna Nikolaus, Mark Ellrichmann, Johannes Bethge
Publikováno v:
BMJ Open Gastroenterology
Inflammatory bowel disease is frequently associated with spondylarthritis (SpA). It has been discussed that α4/β7 expressing lymphocytes are involved in the aetiology of SpA. We report a case of a successful combination therapy of vedolizumab (VDZ)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5faad8cffad6d433e7caf4540c71bedd
https://doi.org/10.1136/bmjgast-2016-000127
https://doi.org/10.1136/bmjgast-2016-000127
Autor:
Mark Ellrichmann, Susanna Nikolaus, Claudio Conrad, Johannes Bethge, Dörthe Schuldt, Sebastian Zeissig, Stefan Schreiber, Rainer Noth
Publikováno v:
Gastroenterology. 146:S-594
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b363c6e8e7f98e3e4f93d08e57c272b1
https://doi.org/10.1016/s0016-5085(14)62152-1
https://doi.org/10.1016/s0016-5085(14)62152-1